Lupin to acquire rights to Brovana and Xopenex HFA for $75m


Lupin Limited has agreed to acquire all rights to a couple of inhalation medicines, namely Brovana (arformoterol tartrate) Inhalation Solution and Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, from Sunovion Pharmaceuticals for $75 million.

The Indian pharma company anticipates the deal to be incremental to earnings in the first year.

According to Lupin, the acquisition of Brovana and Xopenex HFA broaden its portfolio of inhalation products in the US. Besides, it will bolster its footprint in the area of respiratory therapies.

See also  BlackRock acquires organics-to-renewable energy firm Vanguard Renewables

Brovana has approval in the US for the long-term maintenance treatment of bronchoconstriction in people having chronic obstructive pulmonary disease, including emphysema and chronic bronchitis.

On the other hand, the short-acting beta2-adrenergic agonist (SABA) Xopenex HFA has approval in the US for the treatment or prevention of bronchospasm in adults, adolescents, and children aged four and beyond who have reversible obstructive airway disease.

See also  Carbonvert sells Bayou Bend carbon capture project in Texas to Equinor

Vinita Gupta — Lupin CEO said “We remain focused on strengthening our respiratory franchise in the U.S. We have established a strong position in the respiratory segment with our Albuterol MDI and Brovana authorized generic launch. The addition of these two brands enhances our position in the segment.”

Share This